A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

NCT00643292

Last updated date
Study Location
Pfizer Investigational Site
Jonesboro, Arkansas, 72401, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Otitis Media
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-48 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Outpatients with clinical evidence of acute otitis media who weigh at least 5 kg were included

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Patients with previously diagnosed disease of immune function, treatment with any systemic
antibiotic within the previous 7 days, or cleft lip/palate or other anatomic abnormality
predisposing to otitis media were excluded.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Otitis MediaPharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media
NCT00796224
  1. San Jose,
  2. San Jose,
ALL GENDERS
6 Months+
years
MULTIPLE SITES
Acute Otitis MediaA Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections
NCT00643292
  1. Jonesboro, Arkansas
  2. Little Rock, Arkansas
  3. Bellflower, California
  4. Fountain Valley, California
  5. Fresno, California
  6. Fresno, California
  7. Huntington Beach, California
  8. Newhall, California
  9. Orange, California
  10. Paramount, California
  11. Pico Rivera, California
  12. Bridgeport, Connecticut
  13. Hartford, Connecticut
  14. Chicago, Illinois
  15. Chicago, Illinois
  16. Evanston, Illinois
  17. Bardstown, Kentucky
  18. Springfield, Kentucky
  19. Pittsburgh, Pennsylvania
  20. Dallas, Texas
  21. Payson, Utah
  22. Springville, Utah
  23. Vienna, Virginia
  24. Buenos Aires,
  25. Independencia, Santiago
  26. Recoleta, Santiago
  27. Santiago,
  28. San Jose,
  29. Santo Domingo, DN
  30. Pärsti vald, Viljandimaa
  31. Rakvere,
  32. Tallinn,
  33. Tartu,
  34. Guatemala,
  35. Haifa,
  36. Jerusalem,
  37. Petach Tikva,
  38. Tel Hashomer,
  39. Chihuahua,
  40. Ciudad de Panama,
  41. Chorzow,
  42. Lublin,
  43. Moscow,
  44. Moscow,
  45. Smolensk,
  46. Kosice,
  47. Martin,
ALL GENDERS
3 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis
Brief Summary A phase 3 randomized, multicenter, double blind, double dummy study to assess the efficacy, safety, and compliance of a single dose of azithromycin extended release compared with a 10-day course of amoxicillin/clavulanate twice daily in children at high risk for persistent or recurrent ear infections
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Acute Otitis Media
Intervention  ICMJE
  • Drug: amoxicillin/clavulanate postassium (Augmentin ES-600)
    amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
  • Drug: azithromycin SR
    azithromycin SR 60 mg/kg x 1 dose
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: amoxicillin/clavulanate postassium (Augmentin ES-600)
  • Experimental: 2
    Intervention: Drug: azithromycin SR
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 19, 2008)
902
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

Outpatients with clinical evidence of acute otitis media who weigh at least 5 kg were included

Exclusion Criteria:

Patients with previously diagnosed disease of immune function, treatment with any systemic antibiotic within the previous 7 days, or cleft lip/palate or other anatomic abnormality predisposing to otitis media were excluded.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 3 Months to 48 Months   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Chile,   Costa Rica,   Dominican Republic,   Estonia,   Guatemala,   Israel,   Mexico,   Panama,   Poland,   Russian Federation,   Slovakia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00643292
Other Study ID Numbers  ICMJE A0661073
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP